Refining the use of cytoreductive nephrectomy in metastatic renal cell carcinoma

Jeffrey La Rochelle, Christopher Wood, Axel Bex

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cellcarcinoma (mRCC) in the cytokine era. After the introduction of therapies targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, improved median survival and primary tumor responses are observed. Prognostic models have been validated and the clinical significance of tumor heterogeneity and histological subtypes has been recognized. These changes in the understanding and treatment of mRCC require assessment of CN. This review discusses the original context in which the efficacy of CN was established and the advances in treatment that have changed that context. Potential refinements in the use of CN that may reduce overall morbidity by limiting its use to those most likely to benefit are reviewed.

Original languageEnglish (US)
Pages (from-to)429-435
Number of pages7
JournalSeminars in Oncology
Volume40
Issue number4
DOIs
StatePublished - Aug 2013

Fingerprint

Nephrectomy
Renal Cell Carcinoma
Kidney
Sirolimus
Standard of Care
Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Cytokines
Morbidity
Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Refining the use of cytoreductive nephrectomy in metastatic renal cell carcinoma. / La Rochelle, Jeffrey; Wood, Christopher; Bex, Axel.

In: Seminars in Oncology, Vol. 40, No. 4, 08.2013, p. 429-435.

Research output: Contribution to journalArticle

La Rochelle, Jeffrey ; Wood, Christopher ; Bex, Axel. / Refining the use of cytoreductive nephrectomy in metastatic renal cell carcinoma. In: Seminars in Oncology. 2013 ; Vol. 40, No. 4. pp. 429-435.
@article{e8d773bf23294501be65056066093515,
title = "Refining the use of cytoreductive nephrectomy in metastatic renal cell carcinoma",
abstract = "Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cellcarcinoma (mRCC) in the cytokine era. After the introduction of therapies targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, improved median survival and primary tumor responses are observed. Prognostic models have been validated and the clinical significance of tumor heterogeneity and histological subtypes has been recognized. These changes in the understanding and treatment of mRCC require assessment of CN. This review discusses the original context in which the efficacy of CN was established and the advances in treatment that have changed that context. Potential refinements in the use of CN that may reduce overall morbidity by limiting its use to those most likely to benefit are reviewed.",
author = "{La Rochelle}, Jeffrey and Christopher Wood and Axel Bex",
year = "2013",
month = "8",
doi = "10.1053/j.seminoncol.2013.05.007",
language = "English (US)",
volume = "40",
pages = "429--435",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Refining the use of cytoreductive nephrectomy in metastatic renal cell carcinoma

AU - La Rochelle, Jeffrey

AU - Wood, Christopher

AU - Bex, Axel

PY - 2013/8

Y1 - 2013/8

N2 - Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cellcarcinoma (mRCC) in the cytokine era. After the introduction of therapies targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, improved median survival and primary tumor responses are observed. Prognostic models have been validated and the clinical significance of tumor heterogeneity and histological subtypes has been recognized. These changes in the understanding and treatment of mRCC require assessment of CN. This review discusses the original context in which the efficacy of CN was established and the advances in treatment that have changed that context. Potential refinements in the use of CN that may reduce overall morbidity by limiting its use to those most likely to benefit are reviewed.

AB - Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cellcarcinoma (mRCC) in the cytokine era. After the introduction of therapies targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, improved median survival and primary tumor responses are observed. Prognostic models have been validated and the clinical significance of tumor heterogeneity and histological subtypes has been recognized. These changes in the understanding and treatment of mRCC require assessment of CN. This review discusses the original context in which the efficacy of CN was established and the advances in treatment that have changed that context. Potential refinements in the use of CN that may reduce overall morbidity by limiting its use to those most likely to benefit are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=84883171933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883171933&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2013.05.007

DO - 10.1053/j.seminoncol.2013.05.007

M3 - Article

C2 - 23972706

AN - SCOPUS:84883171933

VL - 40

SP - 429

EP - 435

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4

ER -